Acorda Drops Epilepsy Candidate Once Central To Its Revenue Forecasts
This article was originally published in The Pink Sheet Daily
Executive Summary
Plumiaz, a nasal spray formulation of diazepam, is discontinued after it fails one of three Phase III trials undertaken to comply with 2014 FDA complete response letter.
Register for our free email digests: